Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

More ANDAs To Be Eligible For Priority Review, Gottlieb Says

08 Nov 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

FDA Offers To Expedite 'Priority' ANDA Reviews By Previewing Facility Information

26 Jun 2017

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

05 Aug 2017

Generic Combination Products May Be Permitted Delivery Device Variations

05 Jun 2017

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

16 May 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

28 Jun 2017

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

27 Jul 2015

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

24 Sep 2016

Additional Topics

United States Generic Drugs Review Pathway Regulation FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.